Harliku (nitisinone): first FDA-approved disease-modifying therapy for alkaptonuria
Open Access
- 6 October 2025
- journal article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (12) , 7877-7879
Abstract
Alkaptonuria (AKU) is a rare autosomal recessive metabolic disorder due to a deficiency of homogentisate 1,2-dioxygenase, subsequently leading to the progressive acquisition of ochronosis, osteoarthropathy, systemic complications, and the pathological retention of homogentisic acid (HGA). Until recently, apart from supportive management which involved orthopedic surgery and symptomatic treatment, there was no attempt to slow the progress of the disease. On 19 June 2025, the U.S. Food and Drug Administration approved Harliku (nitisinone) as the first therapy to modify the progression of the disease. As a competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase, nitisinone exerts biochemical efficacy with a greater than 95% reduction of urinary excretion of HGA. The SONIA 2 and other studies funded by the NIH have demonstrated long-standing metabolic control with nitisinone, as well as improved functional outcomes and possibly cardioprotective effects. Although the evidence of long-term benefits is promising, risks of treatment, such as tyrosinemia, require attention to diet and continued monitoring. As the first single agent to be taken orally once daily, Harliku changes the paradigm of management for the rare metabolic disorder AKU from symptomatic treatment to disease-modifying therapy. It is a huge leap for other disorders of metabolism and paves the way for future innovations in therapy.Keywords
This publication has 10 references indexed in Scilit:
- Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trialThe Lancet Diabetes & Endocrinology, 2020
- Alkaptonuria: Current PerspectivesThe Application of Clinical Genetics, 2020
- Response to Gurevich and colleagues: The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of expertsMolecular Genetics and Metabolism Reports, 2019
- Open-Label Single-Sequence Crossover Study Evaluating Pharmacokinetics, Efficacy, and Safety of Once-Daily Dosing of Nitisinone in Patients with Hereditary Tyrosinemia Type 12017
- Recent advances in management of alkaptonuria (invited review; best practice article)Journal of Clinical Pathology, 2013
- A 3-year randomized therapeutic trial of nitisinone in alkaptonuriaMolecular Genetics and Metabolism, 2011
- An update on molecular genetics of Alkaptonuria (AKU)Journal of Inherited Metabolic Disease, 2011
- Pricing and reimbursement of orphan drugs: the need for more transparencyOrphanet Journal of Rare Diseases, 2011
- Natural History of AlkaptonuriaNew England Journal of Medicine, 2002
- Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenaseThe Lancet, 1992